RSS Feeds
Thrombogenic Materials in Prothrombin Complex Concentrates
- PHILIP M. BLATT, M.D.;
- ROGER L. LUNDBLAD, Ph.D.;
- HENRY S. KINGDON, M.D., Ph.D.;
- GEORGE McLEAN, M.D.; and
- HAROLD R. ROBERTS, M.D.
Abstract
Prothrombin complex concentrates are now available for use for treatment of bleeding complications associated with deficiencies of factors II, VII, IX, or X. The purpose of this report is to describe a patient who died immediately after the infusion of such a concentrate. Postmortem studies showed that the cause of death was diffuse thromboembolism. Laboratory studies on the concentrate were done after the patient's death and revealed the presence of "clot-accelerating factors." Their presence suggests that the infused material was thrombogenic. In view of the potential hazards associated with these concentrates, guidelines are suggested for their continued use.
Article and Author Information
-
*Proplex®, Hyland Laboratories, Costa Mesa, California.
-
▸From the Departments of Medicine, Pathology, and Biochemistry and the Dental Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
-
Grant support: in part by National Institutes of Health grants HL 06350, DE 02668, RR 05333, HL 16633, and AM 05345.
-
▸Address reprint requests to Philip M. Blatt, M.D., Department of Medicine, University of North Carolina, Chapel Hill, NC 27514.
-
- Received July 8, 1974.
- Accepted September 9, 1974.
Related Clinical Content
